Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. N-(11-cyano-2,2,6a,6b,9,9,12a-heptmethyl-10,14-dioxo-1,3,4,5,6a,6b,7,8,8a,9,10,12a,14,14a,14b-hexadecahydro-2h-picen-4a-yl)-2-2-difluoropropionamide
2. Rta 408
3. Rta-408
1. 1474034-05-3
2. Rta-408
3. Rta 408
4. Nrf1-activator-1
5. Omaveloxolone [inn]
6. Rta408
7. G69z98951q
8. N-[(4as,6ar,6bs,8ar,12as,14ar,14bs)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicen-4a-yl]-2,2-difluoropropanamide
9. Propanamide, N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoro-
10. N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoropropanamide
11. Unii-g69z98951q
12. Omaveloxolone (usan/inn)
13. Omaveloxolone [usan]
14. Omaveloxolone [who-dd]
15. Gtpl7573
16. Chembl4303525
17. Schembl15349371
18. Ex-a541
19. Dtxsid101138251
20. Bcp28609
21. Mfcd28167769
22. Akos037648676
23. Zinc144682962
24. Db12513
25. Bs-15146
26. Hy-12212
27. N-(11-cyano-2,2,6a,6b,9,9,12a-heptmethyl-10,14-dioxo-1,3,4,5,6a,6b,7,8,8a,9,10,12a,14,14a,14b-hexadecahydro-2h-picen-4a-yl)-2-2-difluoropropionamide
28. D10964
29. Rta408; Rta408; Rta-408;nrf1-activator-1
30. Q21098900
31. N-((4as,6ar,6bs,8ar,12as,14ar,14bs)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide
Molecular Weight | 554.7 g/mol |
---|---|
Molecular Formula | C33H44F2N2O3 |
XLogP3 | 6.7 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 2 |
Exact Mass | 554.33199959 g/mol |
Monoisotopic Mass | 554.33199959 g/mol |
Topological Polar Surface Area | 87 Ų |
Heavy Atom Count | 40 |
Formal Charge | 0 |
Complexity | 1320 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 7 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Regulatory Info : RX
Registration Country : USA
Brand Name : SKYCLARYS
Dosage Form : CAPSULE;ORAL
Dosage Strength : 50MG
Packaging :
Approval Date : 2023-02-28
Application Number : 216718
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : Norway
Brand Name : Skyclary's
Dosage Form : Kapsel, hard
Dosage Strength : 50 mg
Packaging : Boks 90item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Global Sales Information
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Omaveloxolone manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Omaveloxolone, including repackagers and relabelers. The FDA regulates Omaveloxolone manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Omaveloxolone API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Omaveloxolone supplier is an individual or a company that provides Omaveloxolone active pharmaceutical ingredient (API) or Omaveloxolone finished formulations upon request. The Omaveloxolone suppliers may include Omaveloxolone API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Omaveloxolone as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Omaveloxolone API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Omaveloxolone as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Omaveloxolone and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Omaveloxolone NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Omaveloxolone suppliers with NDC on PharmaCompass.
Omaveloxolone Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Omaveloxolone GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Omaveloxolone GMP manufacturer or Omaveloxolone GMP API supplier for your needs.
A Omaveloxolone CoA (Certificate of Analysis) is a formal document that attests to Omaveloxolone's compliance with Omaveloxolone specifications and serves as a tool for batch-level quality control.
Omaveloxolone CoA mostly includes findings from lab analyses of a specific batch. For each Omaveloxolone CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Omaveloxolone may be tested according to a variety of international standards, such as European Pharmacopoeia (Omaveloxolone EP), Omaveloxolone JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Omaveloxolone USP).
LOOKING FOR A SUPPLIER?